IP Verse

Celgene Corporation patent opposition analysis

Latest patents of Celgene Corporation opposed by its competitors

The following table provides an overview of the latest patents of Celgene Corporation that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3782612Nov 8, 2023Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof5
EP3370729Sep 27, 2023Methods For The Identification, Evaluation And Treatment Of Patients Having Multiple Myeloma1
EP2651400Jan 18, 2023Controlled Release Oral Dosage Forms Of Poorly Soluble Drugs And Uses Thereof1
EP3880802Sep 7, 2022Improved T Cell Manufacturing Process1
EP3782611Jul 6, 2022Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof5
EP3692983Aug 11, 2021Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof6
EP3320902Feb 17, 2021Methods For Treating Diseases Using Isoindoline Compounds1
EP2797581May 6, 2020Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione3
EP2695609Dec 11, 2019Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof4
EP2687213Jul 17, 2019Solid Forms Comprising (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione, Compositions Thereof, And Uses Thereof1

Top competitors of Celgene Corporation